Get the Stockscreener App
4.10
3.98%
-0.17
Prime Medicine Inc stock is traded at $4.10, with a volume of 2.17M.
It is down -3.98% in the last 24 hours and up +15.49% over the past month.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
See More
Previous Close:
$4.27
Open:
$4.38
24h Volume:
2.17M
Relative Volume:
0.56
Market Cap:
$740.09M
Revenue:
-
Net Income/Loss:
$-217.44M
P/E Ratio:
-1.8894
EPS:
-2.17
Net Cash Flow:
$-205.20M
1W Performance:
+9.63%
1M Performance:
+15.49%
6M Performance:
+180.82%
1Y Performance:
+36.21%
1-Day Range:
$4.09
$4.40
1-Week Range:
$3.83
$4.42
52-Week Range:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Name
Prime Medicine Inc
Sector
Industry
Phone
617-465-0013
Address
60 FIRST ST., CAMBRIDGE
Compare PRME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
4.10 | 770.78M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Downgrade | Citigroup | Buy → Neutral |
| May-20-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-20-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| May-20-24 | Initiated | H.C. Wainwright | Buy |
| May-16-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-24 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-24 | Initiated | TD Cowen | Buy |
| Apr-03-24 | Initiated | Wedbush | Outperform |
| Jan-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Oct-09-23 | Initiated | BMO Capital Markets | Outperform |
| Jul-31-23 | Initiated | Guggenheim | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Nov-14-22 | Initiated | Goldman | Neutral |
| Nov-14-22 | Initiated | JP Morgan | Overweight |
| Nov-14-22 | Initiated | Jefferies | Buy |
| Nov-14-22 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prime Medicine Inc Stock (PRME) Latest News
Prime Medicine's Market Cap Up US$161m Following Year Of Insider Stock Buying - simplywall.st
Prime Medicine’s Stock Fluctuations: How Genomic Advances Steer Performance - StocksToTrade
Prime Medicine (NYSE:PRME) Shares Gap UpShould You Buy? - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Gap UpStill a Buy? - MarketBeat
Prime Medicine announces NEJM publication of PM359 data - TipRanks
Prime Medicine (Nasdaq: PRME) reports first-in-human PM359 CGD data in NEJM study - Stock Titan
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Prime Medicine (NYSE:PRME) Stock Price Up 10.2%Still a Buy? - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Up 11.1%Here's What Happened - MarketBeat
Will Prime Medicine Inc. stock deliver better than expected guidance2025 Sector Review & Safe Capital Preservation Plans - Newser
Prime Medicine (PRME) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Prime Medicine (NASDAQ:PRME) Stock Price Down 7.3%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Down 7.2%Here's Why - MarketBeat
PRME: Prime editing advances with focused clinical programs and data expected in 2027 - TradingView — Track All Markets
Prime Medicine (PRME) Competitors and Alternatives 2025 - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference - The Manila Times
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates - MSN
Prime Medicine transferred with Neutral rating at JPMorgan - MSN
How interest rate cuts could boost Prime Medicine Inc. stockQuarterly Trade Summary & Intraday High Probability Alerts - newser.com
How strong is Prime Medicine Inc. stock balance sheetRate Hike & Growth Oriented Trading Recommendations - newser.com
Prime Medicine Target of Unusually High Options Trading (NYSE:PRME) - MarketBeat
How Prime Medicine Inc. stock reacts to job market dataJuly 2025 Analyst Calls & Daily Oversold Stock Bounce Ideas - newser.com
Momentum divergence signals in Prime Medicine Inc. chartJuly 2025 Update & Trade Opportunity Analysis - newser.com
Prime Medicine’s Surprising Performance: Buy or Step Back? - StocksToTrade
Prime Medicine Inc. (PRME) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Published on: 2025-11-19 13:58:58 - newser.com
Prime Medicine (NASDAQ:PRME) Shares Down 5.8%What's Next? - MarketBeat
Prime Medicine (NYSE:PRME) Trading Down 6.1%Should You Sell? - MarketBeat
Technical signs of recovery in Prime Medicine Inc.July 2025 Intraday Action & Daily Stock Trend Reports - newser.com
Tick level data insight on Prime Medicine Inc. volatilityJuly 2025 Retail & Technical Confirmation Trade Alerts - newser.com
Prime Medicine (NASDAQ:PRME) Shares Up 7.7%Should You Buy? - MarketBeat
Is Prime Medicine Inc. stock supported by strong fundamentalsEarnings Risk Summary & Real-Time Volume Analysis Alerts - newser.com
Is Prime Medicine Inc. stock a buy in volatile marketsWeekly Profit Analysis & High Return Stock Watch Alerts - newser.com
Published on: 2025-11-17 03:08:19 - newser.com
FY2025 EPS Estimate for Prime Medicine Increased by Analyst - MarketBeat
Prime Medicine Inc Stock (PRME) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prime Medicine Inc Stock (PRME) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| NELSEN ROBERT | Director |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners X, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| Liu David R. | 10% Owner |
Jun 30 '25 |
Buy |
2.52 |
21,000 |
52,830 |
20,240,945 |
| Liu David R. | 10% Owner |
Jun 23 '25 |
Buy |
2.16 |
21,000 |
45,402 |
20,219,945 |
| Liu David R. | 10% Owner |
Jun 16 '25 |
Buy |
1.49 |
21,000 |
31,196 |
20,198,945 |
| Liu David R. | 10% Owner |
Jun 11 '25 |
Buy |
1.60 |
21,000 |
33,590 |
20,177,945 |
| Brudnick Richard | Chief Business Officer |
May 20 '25 |
Buy |
1.19 |
20,000 |
23,790 |
20,000 |
| LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
| Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):